M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
Nicox to receive up to EUR3m from Kowa as NCX 470 advances to Phase 3 in Japan
Ophthalmology company Nicox SA (Euronext Growth Paris:ALCOX) announced on Tuesday that its Japanese partner, Kowa, has received regulatory approval to initiate Phase 3 clinical trials of NCX 470 for ocular hypertension in Japan.
This milestone triggers a EUR1m payment to Nicox, with a...
If you want to view the full text of this story, you must first purchase archive credits. Return to Archives
New Search